Table 2. Primary and secondary endpoints... | American Society of Hematology

Table 2.

Primary and secondary endpoints

Endpoints	%	Events, n
Primary
6-y OS overall	61
MLD	67
X-ALD	59
GLD	55
6-y EFS overall	59
MLD	66
X-ALD	56
GLD	53
Secondary
Neutrophil engraftment (day 60)*	86.3
Platelet engraftment (day 180)†	68
Graft failure (primary/secondary)	3.6/8.3	6/14
Chimerism (within 100 d)
Full donor	83.2	104
Mixed	16.8	21
CIF of acute GVHD
Stage II-IV	35.3	59
Stage III-IV	20.2	21
CIF of chronic GVHD at 5 y	30.2	44
Limited/extended		28/15

Endpoints	%	Events, n
Primary
6-y OS overall	61
MLD	67
X-ALD	59
GLD	55
6-y EFS overall	59
MLD	66
X-ALD	56
GLD	53
Secondary
Neutrophil engraftment (day 60)*	86.3
Platelet engraftment (day 180)†	68
Graft failure (primary/secondary)	3.6/8.3	6/14
Chimerism (within 100 d)
Full donor	83.2	104
Mixed	16.8	21
CIF of acute GVHD
Stage II-IV	35.3	59
Stage III-IV	20.2	21
CIF of chronic GVHD at 5 y	30.2	44
Limited/extended		28/15

CIF, cumulative incidence function.

Median, 21; range, 11-83.

Median, 52; range, 13-200.